|
Report Date : |
22.02.2013 |
IDENTIFICATION DETAILS
|
Name : |
DR ABIDI PHARMACEUTICAL LABORATORY |
|
|
|
|
Registered Office : |
Dr. Abidi Ave.,
KM 8 Karaj Makhsoos Road Tehran |
|
|
|
|
Country : |
Iran |
|
|
|
|
Date of Incorporation : |
27.08.1947 |
|
|
|
|
Com. Reg. No.: |
17938 |
|
|
|
|
Legal Form : |
Public Joint
Stock |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical finished products
such as oral liquids/syrups, gels, semi-solids, capsules, tablets, and
ointments. |
|
|
|
|
No. of Employees : |
300 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limited : |
203915 USD |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
Iran |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Iran - ECONOMIC OVERVIEW
Iran's economy is marked by statist policies and an inefficient state sector, which create major distortions throughout the system, and reliance on oil, which provides the majority of government revenues. Price controls, subsidies, and other rigidities weigh down the economy, undermining the potential for private-sector-led growth. Private sector activity is typically limited to small-scale workshops, farming, and services. Significant informal market activity flourishes and corruption is widespread. Tehran since the early 1990s has recognized the need to reduce these inefficiencies, and in December 2010 the legislature passed President Mahmud AHMADI-NEJAD's Targeted Subsidies Law (TSL) to reduce state subsidies on food and energy. This was the most extensive economic reform since the government implemented gasoline rationing in 2007. Over a five-year period the bill will phase out subsidies that previously cost Tehran $60-$100 billion annually and mostly benefited Iran's upper and middle classes. Cash payouts of $45 per person to more than 90% of Iranian households mitigated initial widespread resistance to the TSL program, though popular acceptance remains vulnerable to rising inflation. A rise in world oil prices in 2011 increased Iran's oil export revenue by roughly $28 billion over 2010, easing some of the financial impact of international sanctions. However, expansionary fiscal and monetary policies, government mismanagement, the sanctions, and a depreciating currency are fueling inflation, and GDP growth remains stagnant. Iran also continues to suffer from double-digit unemployment and underemployment. Underemployment among Iran''s educated youth has convinced many to seek jobs overseas, resulting in a significant "brain drain.
|
Source : CIA |
Reference: 210215
Company Name: DR ABIDI PHARMACEUTICAL LABORATORY
Address: Dr. Abidi
Ave., KM 8 Karaj Makhsoos Road
Tehran 1389776363
Postal Address:
PO Box: 13445-156
Tel: + 98 21 44522451-4, 44504784-5
Fax: + 98 21 44504787
Website: www.doctor-abidi.com
E-mail: management@doctor-abidi.com
Company was originally started as an
on 27/08/1974
Current Legal Form:
Public Joint Stock
Registration Address: Dr. Abidi Ave., KM 8 Karaj Makhsoos Road
Tehran
IRAN
Registration Number: 17938
Established Date: 27/08/1947
Registration Date: 27/08/1974
Registration Town: Tehran
Currency: Iranian
Riyals
Nominal capital:
50,000,000,000
|
Number of Shares: 5000000 |
Type of Shares: None Selected |
|
Issued Shares: - |
Value per share: 10000 |
Shareholders:
|
Shareholder Name |
Share % |
|
Iran National Investment Co Iran |
|
|
Darou Cobl Iran |
|
|
Public Investors |
|
Name: Mr. Shokrollah
Memariyan
Position within the company: Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi-English
Name: Mrs. Farzaneh
Jalilfar
Position within the company: Vice Chairman
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi- English
Name: Mr. Mohammad Hassan Baradaran
Position within the company: Manager Director
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Vahid Hashem Beyek Mahalati
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mr. Hassan Motamedi
Position within the company: Member
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Name: Mrs. Mozhgan Tavana
Position within the company: Commercial Manager
Country of Birth: Iran
Nationality: Iranian
Can fluently speak: Farsi, English
Manufacture of pharmaceutical finished
products such as oral liquids/syrups, gels, semi-solids, capsules, tablets, and
ointments.
ISO 9001: 1994
Local Reporters consider the investigated company to be Large in their field of concern
Company Employs: 300
Sales: 90%
Nationally, 10% International
Sales to:
Group
companies, General Public
Sales Term:
Cash, Bank Transfer, accept credit, Letter of
credit
Vehicles: 15
Operates Form: Owned: Offices, Warehouse, and Factory, Laboratory
Location: Central Business
Area, Main Road,
Branch:
No.14, 11th East, Etehad St, Abali Ave, Tehran, Iran
Tel: 98 21 77349794-5
Unite 4, No59,
Oppsite Jahan Kodak pharmactul, Haghani Highway, Tehran, Iran
Tel: 98 88678125-6
Bank Mellat
Tehran
Iran
Bank Saderat
Tehran
Iran
Information Financial is not available/applicable
Imports From: USA, UK
Importing Terms: Bank Transfer
Import % and type of product: 40% Raw Materials
Export To: CIS
Exporting
Terms: Bank Transfer
Export% and type
product: 10% Finished Goods
Subsidiaries:
Dr. Abidi Cosmetic Co
Tehran, Iran
Affiliated:
Daro Pakhash
Tehran, Iran
Auditor: Tadvin Hamkaran Financial Organization
Solicitor: Dariya Ravesh Financial Organization
Subject's payments reported to be: NO COMPLAINTS
Name/Title: Mrs. Mozhgan Tavana (Commercial Manager)
Subject has confirmed the general details provided in the report.
Reporter Comment:
In the interview conducted with, Mrs. Mozhgan Tavana (Commercial Manager), she declined bank account numbers and financial details citing the grounds of company confidentiality.
Local Reputation:
The company being investigated is considered by local reporters to be a Normal
Trade Risk
Local informants consider granting of credit to be a fair trade risk
Owner/Shareholders Comments: Some of the owners / shareholders have an active participation in the running of the business.
Age of Business: Old business
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.48 |
|
|
1 |
Rs.82.71 |
|
Euro |
1 |
Rs.72.23 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.